Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.3
Journals
JCM
Special Issues
Comprehensive Approaches in Gastrointestinal Oncology: Focus on Colorectal, Gastric, and...
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Comprehensive Approaches in Gastrointestinal Oncology: Focus on Colorectal, Gastric, and Pancreatic Cancer Treatment

A Special Issue of Journal of Clinical Medicine (ISSN 2077-0383) belonging to the section "Oncology".

Deadline for manuscript submissions: 15 October 2026 | Viewed by 1083

Editors

Dr. Stefano Rausei

E-Mail Website
Guest Editor
General Surgery Unit, Department of Surgery, Cittiglio-Angera Hospital, ASST SetteLaghi, 21100 Varese, Italy
Interests: surgical oncology; gastric cancer; colon cancer; minimally invasive surgery; emergency surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Georgios D. Lianos

E-Mail Website
Guest Editor
Department of Surgery, University of Ioannina, Ioannina, Greece
Interests: surgical oncology; gastric cancer; colon cancer; minimally invasive surgery; emergency surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Gastrointestinal oncology increasingly relies on a translational framework that connects molecular discoveries to clinical decision-making. Particularly, in colorectal, gastric, and pancreatic cancer, a coordinated multidisciplinary and translational strategy represents the most effective road to improving patients' prognosis. Preclinical findings are rapidly translated into clinical trials with a biomarker-driven approach, converting biological complexity into personalized therapeutic strategies.

On the other hand, clinical management requires a multidisciplinary team including surgeons, oncologists, gastroenterologists, radiologists, as well as molecular pathologists. Necessarily, this team will be able to integrate all the info about the patient's disease in order to identify the most correct solution to cure it, both for its microscopic and macroscopic aspects.

Certainly, the complexity of these topics requires a lot of different competencies. International collaborations lead to the definition of guidelines and enable data sharing across diverse populations. Scientific publishing diffuses knowledge and in turn stimulates new research and new project.

This Special Issue aims to present and disseminate the most recent advances related to the management of colorectal, gastric, and pancreatic cancer. We consider contributions addressing translational research with clear clinical implications, new insights about staging modalities and multidisciplinary and multimodal treatment strategies, and future perspectives of surgical approaches. Contributions about technological innovations without potential direct patient benefit will be discouraged.   

Topics of interest for publication include, but are not limited to, the following:

Colorectal cancer, gastric cancer, pancreatic cancer, biological staging, clinical staging, early tumors, locally advanced tumors, oligometastatic tumors, neoadjuvant approach, chemotherapy, radiotherapy, immunotherapy, radical surgery, conservative treatment, and targeted therapy.

Prof. Dr. Stefano Rausei
Dr. Georgios D. Lianos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colorectal cancer
  • gastric cancer
  • pancreatic cancer
  • biological staging
  • clinical staging
  • early tumors
  • locally advanced tumors
  • oligometastatic tumor
  • neoadjuvant approach
  • chemotherapy
  • radiotherapy
  • immunotherapy
  • radical surgery
  • conservative treatment
  • targeted therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

21 pages, 2434 KB  
Article
Days Alive and out of Hospital at 30 Days After Curative Gastrectomy for Gastric Adenocarcinoma: Complication-Severity Gradient and Readmission Burden
by Adem Ozcan, Gizem Gunes, Ali Bal and Abdulkadir Unsal
J. Clin. Med. 2026, 15(17), 6811; https://doi.org/10.3390/jcm15176811 - 2 Sep 2026
Abstract
Background/Objectives: Days alive and out of the hospital at 30 days (DAOH30) integrates survival, index hospitalization, and readmission. We characterized DAOH30 after gastrectomy, assessed its complication-severity gradient and readmission burden, and explored its association with an index-cancer-excluded Charlson Comorbidity Index (CCI). Methods: This [...] Read more.
Background/Objectives: Days alive and out of the hospital at 30 days (DAOH30) integrates survival, index hospitalization, and readmission. We characterized DAOH30 after gastrectomy, assessed its complication-severity gradient and readmission burden, and explored its association with an index-cancer-excluded Charlson Comorbidity Index (CCI). Methods: This single-center retrospective analysis included adults undergoing R0 total gastrectomy or subtotal distal gastrectomy for non-metastatic gastric adenocarcinoma between January 2020 and April 2026. DAOH30 was derived from the index postoperative length of stay, readmission days, and 30-day mortality. Rank-based tests and median quantile regression were used. Results: Among 123 patients, median DAOH30 was 21 days (interquartile range, 18–22; range, 4–26). No 30-day deaths occurred; eight patients (6.5%) were readmitted. Median DAOH30 decreased from 22 days without complications to 21 days after Clavien–Dindo grade I–II complications and 17 days after grade ≥ III complications (Kruskal–Wallis p < 0.001; one-sided Jonckheere–Terpstra p < 0.001; two-sided permutation sensitivity p < 0.001). After adjustment, grade ≥ III complications were associated with 4.00 fewer median DAOH30 days (bootstrap 95% confidence interval, −7.31 to −2.25; model-based p < 0.001). Readmissions contributed 73 additional inpatient days, with a median decrement of 9.5 days per readmitted patient. No statistically significant independent association was detected between the index-cancer-excluded CCI and DAOH30 (adjusted median difference, −0.17 days per point; bootstrap 95% confidence interval, −1.34 to 0.40; model-based p = 0.640). Conclusions: DAOH30 summarized early hospital burden, but in this no-mortality, low-readmission cohort it was largely determined by index length of stay. Multicenter validation with patient-reported anchoring is warranted. Full article
(This article belongs to the Special Issue Comprehensive Approaches in Gastrointestinal Oncology: Focus on Colorectal, Gastric, and Pancreatic Cancer Treatment)
►▼ Show Figures

Figure 1

Review

Jump to: Research

36 pages, 1175 KB  
Review
Circulating Tumor DNA for Minimal Residual Disease Detection and Recurrence Prediction in Upper Gastrointestinal Cancers: A Scoping Review
by Loizos Hadjigeorgiou, Melina Yerolatsite, Nanteznta Torounidou, George Zarkavelis, Dimitrios Schizas, Vasileios Tatsis, Stefano Rausei, Konstantinos Vlachos and Georgios D. Lianos
J. Clin. Med. 2026, 15(16), 6222; https://doi.org/10.3390/jcm15166222 - 11 Aug 2026
Viewed by 352
Abstract
Circulating tumor DNA (ctDNA) is a promising non-invasive biomarker for detecting minimal residual disease (MRD) and predicting recurrence after curative treatment, yet evidence in esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC), and gastric cancer has largely been examined within individual tumor types. [...] Read more.
Circulating tumor DNA (ctDNA) is a promising non-invasive biomarker for detecting minimal residual disease (MRD) and predicting recurrence after curative treatment, yet evidence in esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC), and gastric cancer has largely been examined within individual tumor types. In this scoping review, we mapped this evidence across all three malignancies and clarified key methodological and clinical considerations. Following the PRISMA-ScR guidelines, we searched PubMed, Scopus, and the Cochrane Library (3 April 2026) for studies linking ctDNA to disease-free, recurrence-free, or overall survival after curative-intent treatment. Twenty-seven studies (1746 patients; 10 ESCC, 4 EAC, 8 gastric, and 5 mixed) were included. Across every tumor type, postoperative ctDNA MRD was the most informative timepoint, with independent multivariable hazard ratios for disease-free, recurrence-free, or event-free survival of 2.8 to 21.8, whereas preoperative ctDNA was seldom prognostic. Serial monitoring further improved performance and flagged recurrence 78 to 278 days before imaging. Tumor-informed assays showed higher sensitivity than tumor-agnostic ones (80% vs. 35%), though direct comparisons were limited; correction for clonal hematopoiesis was essential for tumor-agnostic assays, and blood-based assays performed poorly in diffuse-type and peritoneal disease. Postoperative ctDNA MRD is a consistent, independent prognostic biomarker across upper gastrointestinal cancers that adds prognostic information beyond conventional staging and pathological response, supporting prospective interventional trials of ctDNA-guided management. Full article
(This article belongs to the Special Issue Comprehensive Approaches in Gastrointestinal Oncology: Focus on Colorectal, Gastric, and Pancreatic Cancer Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop